 
 
EXPLANATION:  CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW . 
        [Brackets ] indicate matter deleted from existing law.             *sb0078*      
SENATE BILL 78  
J1   6lr1485  
  (PRE –FILED)    
By: Senator Ellis  
Requested: October 30, 2025  
Introduced and read first time: January 14, 2026  
Assigned to: Finance  
 
A BILL ENTITLED  
 
AN ACT concerning  1 
 
Public Health – Prostate –Specific Antigen Testing  2 
(Protect Our Prostate Act)  3 
 
FOR the purpose of requiring certain providers and laboratories to provide certain written 4 
information to patients receiving prostate –specific antigen testing; requiring clinical 5 
laboratories that administer prostate –specific antigen tests to follow certain 6 
disclosure requirements, use standard calibration for testing assays and report test 7 
results in a standard manner, make certain disclo sures to ordering providers, and 8 
follow guidelines from certain organizations; and generally relating to  9 
prostate –specific antigen testing.  10 
 
BY adding to  11 
 Article – Health – General  12 
Section 17–801 through  17–803 to be under the new subtitle “Subtitle 8.  13 
Prostate –Specific Antigen Test ing” 14 
 Annotated Code of Maryland  15 
 (2023 Replacement Volume and 2025 Supplement)  16 
 
Preamble  17 
 
 WHEREAS , Prostate –specific antigen testing, while an important tool for the early 18 
detection of prostate cancer, is not a definitive  diagnostic tool and can produce misleading 19 
results  that could lead to invasive biopsies or overtreatment ; and  20 
 
 WHEREAS, Patients undergoing prostate –specific antigen testing should be 21 
adequately informed of the potential costs associated with the testing  and the implications 22 
surrounding false –positive results ; now, therefore,  23 
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 24 
That the Laws of Maryland read as follows:  25 
2 SENATE BILL 78   
 
  
Article – Health – General  1 
 
SUBTITLE 8. PROSTATE –SPECIFIC ANTIGEN TESTING . 2 
 
17–801. 3 
 
 (A) IN THIS SUBTITLE THE FOLLOWING WORD S HAVE THE MEANING  4 
INDICAT ED. 5 
 
 (B) “CLINICAL LABORATORY ” MEANS A FACILITY IN WHICH  LABORATORY 6 
TESTING IS PERFORMED ON HUMAN SPECI MENS FOR DIAGNOSIS , PREVENTION , OR 7 
TREATMENT OF DISEASE . 8 
 
 (C) “PROSTATE –SPECIFIC ANTIGEN TES T” MEANS A LABORATORY B LOOD 9 
TEST THAT MEASURES T HE CONCENTRATION OF PROSTATE –SPECIFIC ANTIGEN FOR  10 
USE IN DIAGNOSING A PROSTATE DISORDER . 11 
 
17–802. 12 
 
 (A) IF A PROVIDER ORDERS A PROSTATE –SPECIFIC ANTIGEN TES T FOR A 13 
PATIENT  DURING A PATIENT ENC OUNTER , THE PROVID ER SHALL PROVIDE WRITTE N 14 
INFORMATION TO THE P ATIENT RELATING TO T HE NECESSARY PREPARATION FOR 15 
ENSURING ACCURATE TE ST RESULTS . 16 
 
 (B) IF A CLINICAL LABORAT ORY OFFERS PROSTATE –SPECIFIC ANTIGEN 17 
TESTING WITHOUT A PR OVIDER ORDER  FROM A PATIENT ENCOU NTER , THE 18 
LABORATORY IN WHICH BLOOD IS DR AWN FOR THE TEST  SHALL PROVIDE WRITTE N 19 
INFORMATION TO THE P ATIENT RELATING TO T HE NECESSARY PREPARATION FOR 20 
ENSURING ACCURATE TE ST RESULTS THAT SHALL ALSO BE MADE : 21 
 
  (1) NOT LATER THAN 3 DAYS BEFORE  A SCHEDULED APPOINTM ENT; 22 
AND 23 
 
  (2) AVAILABLE T HROUGH IN –PERSON EDUCATION . 24 
 
17–803. 25 
 
 A CLINICAL LABORATORY ADMINISTERING A PROS TATE–SPECIFIC ANTIGEN 26 
TEST SHALL : 27 
 
  (1) USE TESTING ASSAYS THAT HAVE BEEN APPROVED B Y THE U.S.  28 
FOOD AND DRUG ADMINISTRATION ; 29 
 
 SENATE BILL 78  3 
 
   (2) IMPLEMENT CALIBRATION  OF PROSTATE –SPECIFIC ANTIGEN 1 
TEST ASSAYS USING WORLD HEALTH ORGANIZATION INTERNATIONAL STANDARDS 2 
OR ANOTHER NATIONALL Y RECOGNIZED REFEREN CE STAND ARD; 3 
 
  (3) REPORT PROSTATE –SPECIFIC ANTIGEN TEST RESULTS IN 4 
NANOGRAMS PER MILLIL ITER AND INCLUDE ANY  REFERENCE RANGE UNIQ UE TO 5 
THE TESTING ASSAY US ED; 6 
 
  (4) DOCUMENT AND DISCLOSE  TO THE ORDERING PROV IDER THE 7 
TEST METHODOLOGY , MANUFACTURER , AND LOT NUMBER OF TH E TESTING ASSAY 8 
USED ; AND 9 
 
  (5) PARTICIPATE IN A CLIN ICAL TESTING PROFICI ENCY PROGRAM 10 
RELATING TO PROSTATE –SPECIFIC ANTIGEN TES TS THAT IS RECOGNIZED BY THE 11 
CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OR THE COLLEGE OF 12 
AMERICAN PATHOLOGISTS . 13 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July 14 
1, 2026.  15 